Diagnostic and risk stratification aspects of liver fibrosis progression in chronic hepatitis B and C viral infection

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The treatment strategy and prognosis for chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection largely depend on the presence and stage of liver fibrosis. This study aimed to reveal the diagnostic and risk stratification aspects of liver fibrosis progression in patients with chronic HBV and HCV infection. The PubMed database, the Google Scholar search engine, the Cochrane systematic reviews, and the scientific electronic library eLibrary.Ru, as well as the reference lists, were used to search for scientific articles. Relevant aims of the publication review were selected over the period from 2005 to 2021 using the keywords “chronic HBV infection,” “chronic HCV infection,” “liver fibrosis,” “diagnostics,” and “prognosis.” Inclusion criteria were limited to liver fibrosis diagnostics in chronic HBV and HCV infection. Considering biopsy as a gold standard for studying morphological abnormalities in the liver, its indications for serum biomarkers of liver fibrosis and imaging methods assessments are currently significantly limited. Additionally, noninvasive methods are required to monitor the progression of liver fibrosis. The combined use of two unrelated noninvasive methods, for example, transient elastography and one of the serum biomarkers, can improve the accuracy of clinically diagnosing significant liver fibrosis. Considering that the development of liver fibrosis is an unfavorable event in the natural course of chronic HBV and HCV infection, the distribution of patients by risk groups will increase the efficiency of antiviral therapy and improve the disease prognosis.

Full Text

Restricted Access

About the authors

Dmitry V. Garbuzenko

South Ural State Medical University

Author for correspondence.
Email: garb@inbox.ru
ORCID iD: 0000-0001-9809-8015

MD, Dr. Sci. (Med.), Professor

Russian Federation, Chelyabinsk

References

  1. Garbuzenko DV. The role of antiviral therapy in the management of patients with liver cirrhosis associated with chronic HBV and HCV infection. Vopr. Virusol. 2021; 66(5): 331–339. (in Russ). doi: 10.36233/0507-4088-70.
  2. European Association for Study of L, Asociacion Latinoamericana para el Estudio del H. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237–264. doi: 10.1016/j.jhep.2015.04.006
  3. Yushchuk ND, Klimova EA, Znoiko OO, et al. Protokol diagnostiki i lecheniya bol''nykh virusnymi gepatitami v i s. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2010;20(6):4–60. (In Russ).
  4. Korean Association for the Study of the L. KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol. 2019;25(2):93–159. doi: 10.3350/cmh.2019.1002
  5. Cornberg M, Lok AS, Terrault NA, et al. Guidance for design and endpoints of clinical trials in chronic hepatitis B – Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference(double dagger). J Hepatol. 2020;72(3):539–557. doi: 10.1016/j.jhep.2019.11.003
  6. European Association for the Study of the Liver. Electronic address eee, Clinical Practice Guidelines Panel C, representative EGB, Panel m. EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol. 2020;73(5):1170–1218. doi: 10.1016/j.jhep.2020.08.018
  7. Ghany MG, Morgan TR, Panel A-IHCG. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020;71(2):686–721. doi: 10.1002/hep.31060
  8. Zeng DW, Dong J, Liu YR, et al. Noninvasive models for assessment of liver fibrosis in patients with chronic hepatitis B virus infection. World J Gastroenterol. 2016;22(29):6663–6672. doi: 10.3748/wjg.v22.i29.6663
  9. Wang H, Xue L, Yan R, et al. Comparison of FIB-4 and APRI in Chinese HBV-infected patients with persistently normal ALT and mildly elevated ALT. J Viral Hepat. 2013;20(4):e3–10. doi: 10.1111/jvh.12010
  10. Li Q, Ren X, Lu C, et al. Evaluation of APRI and FIB-4 for noninvasive assessment of significant fibrosis and cirrhosis in HBeAg-negative CHB patients with ALT ≤ 2 ULN: A retrospective cohort study. Medicine (Baltimore). 2017;96(12):e6336.
  11. doi: 10.1097/MD.0000000000006336
  12. Ma J, Jiang Y, Gong G. Evaluation of seven noninvasive models in staging liver fibrosis in patients with chronic hepatitis B virus infection. Eur J Gastroenterol Hepatol. 2013;25(4):428–434. doi: 10.1097/MEG.0b013e32835cb5dd
  13. Schmoyer CJ, Kumar D, Gupta G, Sterling RK. Diagnostic Accuracy of Noninvasive Tests to Detect Advanced Hepatic Fibrosis in Patients With Hepatitis C and End-Stage Renal Disease. Clin Gastroenterol Hepatol. 2020;18(10):2332–2339 e2331. doi: 10.1016/j.cgh.2020.02.019
  14. Degos F, Perez P, Roche B, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol. 2010; 53(6):1013–1021. doi: 10.1016/j.jhep.2010.05.035
  15. Leroy V, Sturm N, Faure P, et al. Prospective evaluation of FibroTest(R), FibroMeter(R), and HepaScore(R) for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C. J Hepatol. 2014;61(1):28–34. doi: 10.1016/j.jhep.2014.02.029
  16. Marcellin P, Ziol M, Bedossa P, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int. 2009;29(2):242–247. doi: 10.1111/j.1478-3231.2008.01802.x
  17. Stasi C, Arena U, Vizzutti F, et al. Transient elastography for the assessment of liver fibrosis in patients with chronic viral hepatitis: the missing tool? Dig Liver Dis. 2009;41(12):863-866. doi: 10.1016/j.dld.2009.04.002
  18. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142(6):1293–1302 e1294. doi: 10.1053/j.gastro.2012.02.017
  19. Ganne-Carrie N, Ziol M, de Ledinghen V, et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology. 2006;44(6):1511–1517. doi: 10.1002/hep.21420
  20. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008; 48(5):835–847. doi: 10.1016/j.jhep.2008.02.008
  21. Huang LL, Yu XP, Li JL, et al. Effect of liver inflammation on accuracy of FibroScan device in assessing liver fibrosis stage in patients with chronic hepatitis B virus infection. World J Gastroenterol. 2021; 27(7):641–653. doi: 10.3748/wjg.v27.i7.641
  22. Li X, Zheng S, Xu H, Gao P. Evaluation of non-invasive methods in hepatitis B virus (HBV)-infected patients with normal liver function. Int J Clin Exp Med. 2018;11(2):792–798.
  23. Khare S, Arora A, Sharma P, et al. Performance of Non-invasive Blood Parameters for Ruling Out Significant Liver Fibrosis in Patients with Chronic Hepatitis B. J Clin Transl Hepatol. 2020;8(2):143–149. doi: 10.14218/JCTH.2020.00002
  24. Maimone S, Calvaruso V, Pleguezuelo M, et al. An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers. J Viral Hepat. 2009;16(11):769–774. doi: 10.1111/j.1365-2893.2009.01120.x
  25. Sporea I, Sirli RL, Deleanu A, et al. Acoustic radiation force impulse elastography as compared to transient elastography and liver biopsy in patients with chronic hepatopathies. Ultraschall Med. 2011;32 Suppl 1:S46–52. doi: 10.1055/s-0029-1245360
  26. Ueda N, Kawaoka T, Imamura M, et al. Liver fibrosis assessments using FibroScan, virtual-touch tissue quantification, the FIB-4 index, and mac-2 binding protein glycosylation isomer levels compared with pathological findings of liver resection specimens in patients with hepatitis C infection. BMC Gastroenterol. 2020;20(1):314. doi: 10.1186/s12876-020-01459-w
  27. Zhuang Y, Ding H, Zhang Y, et al. Two-dimensional Shear-Wave Elastography Performance in the Noninvasive Evaluation of Liver Fibrosis in Patients with Chronic Hepatitis B: Comparison with Serum Fibrosis Indexes. Radiology. 2017;283(3):873–882. doi: 10.1148/radiol.2016160131
  28. Venkatesh SK, Wang G, Lim SG, Wee A. Magnetic resonance elastography for the detection and staging of liver fibrosis in chronic hepatitis B. Eur Radiol. 2014;24(1):70–78. doi: 10.1007/s00330-013-2978-8
  29. Xu XY, Wang WS, Zhang QM, et al. Performance of common imaging techniques vs serum biomarkers in assessing fibrosis in patients with chronic hepatitis B: A systematic review and meta-analysis. World J Clin Cases. 2019; 7(15):2022–2037. doi: 10.12998/wjcc.v7.i15.2022
  30. Cales P, Boursier J, Lebigot J, et al. Liver fibrosis diagnosis by blood test and elastography in chronic hepatitis C: agreement or combination? Aliment Pharmacol Ther. 2017;45(7):991–1003. doi: 10.1111/apt.13954
  31. Liu Y, Dong CF, Yang G, et al. Optimal linear combination of ARFI, transient elastography and APRI for the assessment of fibrosis in chronic hepatitis B. Liver Int. 2015;35(3):816–825. doi: 10.1111/liv.12564
  32. Wong GL, Wong VW, Choi PC, et al. Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther. 2010;31(10):1095–1103. doi: 10.1111/j.1365-2036.2010.04276.x
  33. Wong GL, Chan HL, Choi PC, et al. Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther. 2014; 39(2):197–208. doi: 10.1111/apt.12559
  34. Boursier J, de Ledinghen V, Zarski JP, et al. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatology. 2012;55(1):58–67. doi: 10.1002/hep.24654
  35. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017; 67(2):370–398. doi: 10.1016/j.jhep.2017.03.021
  36. Zeng DW, Zhang JM, Liu YR, et al. A Retrospective Study on the Significance of Liver Biopsy and Hepatitis B Surface Antigen in Chronic Hepatitis B Infection. Medicine (Baltimore). 2016;95(8):e2503. doi: 10.1097/MD.0000000000002503
  37. Chao DT, Lim JK, Ayoub WS, et al. Systematic review with meta-analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≤ 40 IU/L and significant hepatic fibrosis. Aliment Pharmacol Ther. 2014; 39(4):349-358. doi: 10.1111/apt.12590
  38. Castera L, Bedossa P. How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy? Liver Int. 2011; 31 Suppl 1:13–17. doi: 10.1111/j.1478-3231.2010.02380.x
  39. Loustaud-Ratti V, Debette-Gratien M, Carrier P. European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift. World J Hepatol. 2018;10(10):639–644. doi: 10.4254/wjh.v10.i10.639
  40. Tachi Y, Hirai T, Toyoda H, et al. Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus. PLoS One. 2015;10(7):e0133515. doi: 10.1371/journal.pone.0133515
  41. Suda T, Okawa O, Masaoka R, et al. Shear wave elastography in hepatitis C patients before and after antiviral therapy. World J Hepatol. 2017; 9(1):64–68. doi: 10.4254/wjh.v9.i1.64
  42. Vergniol J, Boursier J, Coutzac C, et al. Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C. Hepatology. 2014;60(1):65–76. doi: 10.1002/hep.27069
  43. Vutien P, Kim NJ, Moon AM, et al. Fibroscan liver stiffness after anti-viral treatment for hepatitis C is independently associated with adverse outcomes. Aliment Pharmacol Ther. 2020;52(11-12):1717–1727. doi: 10.1111/apt.16092
  44. Ahn SH, Park YN, Park JY, et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol. 2005;42(2):188–194. doi: 10.1016/j.jhep.2004.10.026
  45. Andersen ES, Weiland O, Leutscher P, et al. Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs. Scand J Gastroenterol. 2011;46(6):760–766. doi: 10.3109/00365521.2011.565068
  46. Trivedi HD, Lin SC, D TYL. Noninvasive Assessment of Fibrosis Regression in Hepatitis C Virus Sustained Virologic Responders. Gastroenterol Hepatol (N Y). 2017;13(10):587–595. PMC5786821

Supplementary files

Supplementary Files
Action
1. Fig. An algorithm for monitoring patients with chronic viral hepatitis C who have achieved a stable virological response. Source: Trivedi H.D., Lin S.C., Lau D.T.Y. Noninvasive Assessment of Fibrosis Regression in Hepatitis C Virus Sustained Virologic Responders. Gastroenterol Hepatol (N Y). 2017;13(10):587–595.

Download (117KB)

Copyright (c) 2021 Eco-Vector



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies